Isotechnika Inc.'s Phase III Psoriasis Trial Data To Be Presented At Both The Canadian Society Of Transplantation Annual Meeting And The 64th American Academy of Dermatology Annual Meeting

EDMONTON, March 2 /PRNewswire-FirstCall/ - Isotechnika Inc. announced today that the data from the Phase III trials of ISA247 will be presented at both the Canadian Society of Transplantation and 64th American Academy of Dermatology Annual Meetings. Mr. Robert Huizinga, Isotechnika's Senior Director of Clinical Affairs will make an oral presentation entitled 'ISA247: A Calcineurin Inhibitor that Shows Minimal Impact on Renal Function in a Phase III Trial' at the Canadian Society of Transplantation Annual Meeting. Mr. Huizinga's presentation will take place at 11:40 a.m. EST on March 4th, 2006 in the Mali Room at the Fairmont Tremblant Hotel in Mont Tremblant, Quebec.

Isotechnika will also have two principal investigators involved in the Company's Phase III psoriasis trial participate in poster discussions at the 64th American Academy of Dermatology Annual Meeting in San Francisco, California. Dr. Kim Papp's presentation entitled 'A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Study of ISA247 in plaque psoriasis patients' will take place at 7:20 a.m. PT followed by Dr. Norman Wasel's presentation entitled 'Pharmacokinetics and Pharmacodynamics of ISA247 in a Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Study' at 7:50 a.m. PT. Both presentations will take place on Sunday, March 5th in Hall A of the Moscone Center.

Also on display will be a poster exhibit by Dr. Charles Lynde titled 'A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled, Quality of Life Study of ISA247 in Plaque Psoriasis Patients'. All posters will be on display from March 3-6, 2006, and presented on behalf of Isotechnika Inc.

"We are extremely pleased that data from our Phase III psoriasis trials of ISA247 will be presented to audiences that represent both dermatology and transplantation," stated Dr. Randall Yatscoff, Isotechnika's President and Chief Executive Officer. "We continue to be encouraged by the data generated in the SPIRIT extension trial and we believe ISA247 will continue to demonstrate continued efficacy with minimal toxicity."

All interested parties are encouraged to view both the presentations and the posters on our corporate Web site at www.isotechnika.com in the Investor Relations section.

About Isotechnika -----------------

Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in medicinal chemistry and immunology, the Company is focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Its entrepreneurial management and world-class team of scientists are building a pipeline of immunosuppressive drug candidates for treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. Isotechnika looks to become the leader in development of immunosuppressant therapies.

Isotechnika's lead compound, ISA247 is an immunosuppressant currently in an extension protocol of a Canadian Phase III human clinical trial for the treatment of moderate to severe psoriasis. In addition, ISA247 has successfully completed a Phase IIa trial for kidney transplantation. The Company also has an additional immunosuppressive compound in its drug pipeline, TAFA93 which is in Phase I.

Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol ISA. More information on Isotechnika can be found at www.isotechnika.com.

Partnerships ------------

Isotechnika Inc. has a collaboration agreement with Hoffman La Roche which licensed the worldwide rights to develop and commercialize Isotechnika's novel molecule ISA247 for all transplant indications.

In addition, the Company has an exclusive worldwide licensing agreement with Atrium Medical Corporation for the use of ISA247 and TAFA93 specifically with drug eluting devices for the non-systemic treatment of vascular, cardiovascular, target vessel and tissue disorders.

Forward-Looking Statements

--------------------------

This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.

CONTACT: Dr. Randall Yatscoff, President & CEO, Isotechnika Inc., (780)487-1600 (246), (780) 484-4105 (fax), ryatscoff@isotechnika.com; Archivedimages on this organization are searchable through CNW Photo Archivewebsite at http://photos.newswire.ca. Images are free to accredited membersof the media; To request a free copy of this organization's annual report,please go to http://www.newswire.ca and click on Tools for Investors.